Plaque Psoriasis Treatment Market Size, Share & Trend | Industry Analysis Report, 2026

Plaque psoriasis is the most common type of psoriasis and accounts for 80% to 90% cases of total psoriasis. Plaque psoriasis is an autoimmune condition, wherein thick, red patches appear on the skin. These plaques commonly appear on the knees, scalp, and elbows; however, these can also appear on other body part. These are itchy, painful, and can bleed. The exact cause of plaque psoriasis is unknown. The triggers of psoriasis include infections, severe sunburns, stress, smoking, alcohol consumption, obesity, dry skin, and certain medications. The common symptoms of plaque psoriasis include itching, pain, stinging sensation, and skin tightness. Diagnosis of plaque psoriasis is usually done with thorough skin examination. Occasionally, biopsy is also recommended to confirm the condition. Rise in prevalence of psoriasis across the globe, increase in research expenditure in developing countries, high level of unmet clinical needs in patients with psoriasis, surge in awareness about the condition, and favorable reimbursement policies are the major factors projected to drive the global plaque psoriasis treatment market during the forecast period. However, there is no disease modifying treatment available for the conditions and current treatment provides symptomatic relief only. This factor acts as a major restraint of the global plaque psoriasis treatment market.

Report Overview @ https://www.transparencymarketresearch.com/plaque-psoriasis-treatment-market.html

The global plaque psoriasis treatment market can be segmented based on therapy, drug class, and region. In terms of therapy, the plaque psoriasis treatment market can be classified into topical therapy, phototherapy, systemic agents, and biologic therapies. The topical therapy segment dominated the market in 2017 and is projected to sustain its leadership position during the forecast period. This is because topical therapy is considered first line of treatment for plaque psoriasis. Phototherapy involves exposing skin to UV light under medical supervision. Phototherapy and systemic agents are usually prescribed when topical therapy is inadequate. Based on drug class, the global plaque psoriasis treatment market can be categorized into TNF-α inhibitors, IL-17 inhibitors, and IL-12/23 inhibitors. The TNF-α inhibitors segment dominated the market in 2017 due to its safety profile and significant usage in the treatment of plaque psoriasis. The segment is expected to sustain its leadership position between 2018 and 2026. TNF-α inhibitors block body’s response to TNF, a protein produced by white blood cells, thereby suppressing inflammation. These are also used in the treatment of rheumatoid arthritis (RA), Crohn’s disease, psoriatic arthritis, ankylosing spondylitis, and psoriasis.

Request Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=59793

In terms of region, the global plaque psoriasis treatment market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is projected to account for significant share of the global market during the forecast period. Rise in prevalence of plaque psoriasis in the U.S. and rich pipeline of drugs are the major factors anticipated to propel the market in North America from 2018 to 2026. According to the National Psoriasis Foundation, nearly 7.5 million people in the U.S. suffer from psoriasis, and plaque psoriasis is the most common type of the disease. According to the World Psoriasis Day consortium, 125 million people suffer from psoriasis across the globe. The plaque psoriasis treatment market in Asia Pacific is expected to expand at a high CAGR between 2018 and 2026. This can be attributed to increase in research expenditure and rise in awareness about the disease among the population.

Request for TOC @ https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=59793

Key players operating in the global plaque psoriasis treatment market are AbbVie, Inc., Pfizer, Inc., LEO Pharma A/S, Johnson & Johnson Services, Inc., Eli Lilly and Company, UCB S.A., Sun Pharmaceutical Industries Ltd., Celgene Corporation, Merck & Co., Inc., and Novartis AG.